Xenetic Biosciences, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Framingham, MA
XBIO chart
What traders are saying about $XBIO
Latest postsXenetic Biosciences, Inc. news
- Xenetic Biosciences, Inc. Estimates – GETTEX:3XB0
TradingView ·
- XBIO Q2 2025 Earnings: Loss Narrower Than Expected, Yet Shares Slide 10.9% - Earnings Beat Alert
https://www.dars.gov.et/ ·
- Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Yahoo Finance ·
- Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake
investorshub.advfn.com ·
- Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
Yahoo Finance ·
- Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
Yahoo Finance ·
- Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
Yahoo Finance ·
- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Yahoo Finance ·
- Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Yahoo Finance ·
- Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Yahoo Finance ·
- Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
Yahoo Finance ·
- Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Yahoo Finance ·
Xenetic Biosciences, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M |
| Diluted EPS | $-1.58 | $-2.57 | $-2.71 | $-4.61 |
| Total assets (year end) | $8.4M | $6.9M | $10.6M | $14.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Xenetic Biosciences, Inc.
- Ticker
- XBIO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Framingham, MA
- Incorporated in
- NV
- Fiscal year end
- December 31
- SEC CIK
- 1534525
- Former names
- General Sales & Leasing, Inc., GENERAL AIRCRAFT INC.
Frequently asked questions
What exchange is Xenetic Biosciences, Inc. listed on?
Xenetic Biosciences, Inc. trades on the Nasdaq under the ticker symbol XBIO.
What industry is Xenetic Biosciences, Inc. in?
Xenetic Biosciences, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Xenetic Biosciences, Inc. headquartered?
Xenetic Biosciences, Inc.'s business address on file with the SEC is in Framingham, MA.
When does Xenetic Biosciences, Inc.'s fiscal year end?
Xenetic Biosciences, Inc.'s fiscal year ends on December 31.
How much revenue did Xenetic Biosciences, Inc. report?
Xenetic Biosciences, Inc. reported $3.0M in revenue for calendar year 2025, according to its SEC filings.